+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID05126290

Study to Understand Cancer Risks Linked to CTNNA1 Gene Variants Including Gastric and Breast Cancer Through Family and Personal History Analysis

Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-02-05

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the cancer risks linked to specific changes called loss-of-function variants in the CTNNA1 gene. These gene changes may increase the chance of hereditary cancers such as gastric and breast cancer. The study aims to better understand how these genetic changes relate to cancer development and if certain gene types are connected to specific cancer patterns. This knowledge will help improve risk management for individuals carrying these gene variants. Participants will provide personal and family medical history through an online system. The study focuses on people who carry CTNNA1 loss-of-function variants or their first-degree relatives. There is no treatment involved instead, data collection is observational to assess how these gene changes relate to cancer occurrence. During the study, researchers will gather detailed personal and family history information from participants. They will monitor the rate of cancer among gene variant carriers and explore the relationship between CTNNA1 genotypes and cancer types. The study is expected to last about one year, with all participation done through data entry without any medical procedures. Safety and compliance are monitored through questionnaire and data review.

CONDITIONS

Brief Title

CTNNA1 Familial Expansion Study

Research Team

B

Bryson W Katona, MD, PhD

D

Dana Farengo Clark, MS, LCGC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here